Scarica l'app Stockscreener
1,123.00
0.11%
-1.21
Dopo l'orario di chiusura:
1123.06
0.06
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,124.21
Aprire:
$1126.08
Volume 24 ore:
1.99M
Relative Volume:
0.72
Capitalizzazione di mercato:
$1.00T
Reddito:
$72.25B
Utile/perdita netta:
$25.28B
Rapporto P/E:
40.42
EPS:
27.781
Flusso di cassa netto:
$10.37B
1 W Prestazione:
-3.16%
1M Prestazione:
-8.84%
6M Prestazione:
+12.15%
1 anno Prestazione:
+48.82%
Intervallo 1D:
$1,120.52
$1,133.79
Intervallo di 1 settimana:
$1,113.55
$1,158.44
Portata 52W:
$712.05
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,123.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.35 | 643.64B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
255.00 | 443.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.71 | 363.98B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.48 | 261.31B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Why Eli Lilly (NYSE:LLY) Draws Notice As Metabolic-Disease Pipeline Advances - Kalkine Media
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH - The Motley Fool
Got $10,000? Eli Lilly vs. Nvidia: The Better Buy For 2026 - 24/7 Wall St.
Eli Lilly Stock Has Become a Trillion-Dollar Giant. Is It Too Late to Buy? - 24/7 Wall St.
$Eli Lilly and Co (LLY.US)$ - Moomoo
Eli Lilly (NYSE:LLY): Is This Run Still Undervalued? - Kalkine Media
Lilly’s GLP-1 Windfall to Fund Push Into Women’s Health - Bloomberg.com
Lilly’s GLP-1 Windfall to Fund Investments in Women’s Health - The Business of Fashion
HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating - marketscreener.com
Why Is Eli Lilly (NYSE:LLY) Drawing Market Attention? - Kalkine Media
The Zacks Analyst Blog Highlights Eli Lilly, Palo Alto, Texas Instruments and Stratus Properties - Yahoo Finance
Calif. Judge Hands Eli Lilly Mixed Bag In Compound Drug Row - Law360
Top Analyst Reports for Eli Lilly, Palo Alto Networks & Texas Instruments - Yahoo Finance Singapore
Eli Lilly investing hundreds of thousands of dollars to bolster Kenosha manufacturing workforce - The Business Journals
Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks - Yahoo Finance
BMO reiterates Eli Lilly stock rating on incretin growth outlook - Investing.com
BMO reiterates Eli Lilly stock rating on incretin growth outlook By Investing.com - Investing.com UK
Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031 - The Motley Fool
What Is Shaping Interest in Eli Lilly Stock? (NYSE:LLY) - Kalkine Media
Eli Lilly 'Sabotaged' Rezpeg's Development, Nektar Tells Jury - Law360
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Eli Lilly lawsuit against weight-loss drug seller gets another shave - Courthouse News
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years - Benzinga
Here's Why Eli Lilly (LLY) Fell More Than Broader Market - Yahoo Finance
Eli Lilly (NYSE:LLY) Heads Into Conference Season With A Broadening Pipeline - Kalkine Media
ELI LILLY Executive Vice President Eric Dozier Retains 14,239 Shares Following Gift Transaction - Kalkine Media
Eli Lilly scholarship backs Gateway manufacturing students - Kenosha News
Lilly fighting black market for its next obesity drug - The Indiana Lawyer
Eli Lilly (NYSE:LLY): Can New FDA Approvals Fuel Growth? - Kalkine Media
Why Is Eli Lilly Stock Falling Tuesday? - Benzinga
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Eli Lilly vs. Novo Nordisk: One Has 39% Upside. I'm Picking the Other. - Barchart.com
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? - Yahoo Finance
Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 14.46% Upside in the Healthcare Giant - DirectorsTalk Interviews
Eli Lilly expands US pharmaceutical manufacturing with over US$50bn investment - Scientist Live
Eli Lilly’s $100B incretin opportunity: Is more upside coming? - Investing.com
Lilly invests SGD $42M in new Digital Health Hub in Singapore - Singapore Economic Development Board (EDB)
Eli Lilly (LLY) Posts 52 Week Trial Data, Is The Stock Trading At A Discount? - simplywall.st
Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years - The Motley Fool
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. - The Motley Fool
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Lilly looks beyond obesity with $2.88B autoimmune buyout - thestreet.com
The Oral GLP-1 Tracker: Novo's Wegovy pill, Lilly's Foundayo grow scripts - Fierce Pharma
DRUGS AND BIOLOGICS—5th Cir.: Fifth Circuit upholds FDA's removal of tirzepatide from drug shortage list, rejecting compounders' APA challenges - VitalLaw.com
Eli Lilly and Company $LLY Shares Bought by BNP Paribas - insurancenewsnet.com
Eli Lilly Just Announced a Major Acquisition. Here's What It Means. - The Motley Fool
Eli Lilly’s Foundayo Launches in UK Amid Counterfeit Risks - healthcare-digital.com
Lilly to acquire Merida Biosciences for up to $2.875bn - Manufacturing Chemist
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity - MarketBeat
JPMorgan reiterates Eli Lilly stock rating on incretin growth - Investing.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):